Catalogue Number: AB01688-10.3-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | B7.1; CD28L; CD28LG; B7-1; B7; BB1; B7/BB1;T-lymphocyte activation antigen CD80; Activation B7-1 antigen; CTLA-4 counter-receptor B7.1; CTLA4L; CTLA-4L |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Human |
| Clone: | 16C10 |
| Isotype: | IgG1 |
| Immunogen: | This antibody was generated by immunization of cynomolgus monkeys with human B7.1 antigen. |
| Application: | ELISA, Blk |
CD80
941
P33681
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.
This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.